194 related articles for article (PubMed ID: 28038706)
1. Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.
Yabe M; Medeiros LJ; Daneshbod Y; Davanlou M; Bueso-Ramos CE; Moran EJ; Young KH; Miranda RN
Ann Diagn Pathol; 2017 Feb; 26():16-22. PubMed ID: 28038706
[TBL] [Abstract][Full Text] [Related]
2. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
Parakkal D; Sifuentes H; Semer R; Ehrenpreis ED
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
[TBL] [Abstract][Full Text] [Related]
3. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
4. Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
Thai A; Prindiville T
J Crohns Colitis; 2010 Nov; 4(5):511-22. PubMed ID: 21122554
[TBL] [Abstract][Full Text] [Related]
5. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.
Ochenrider MG; Patterson DJ; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):144-8. PubMed ID: 20371449
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
Kotlyar DS; Osterman MT; Diamond RH; Porter D; Blonski WC; Wasik M; Sampat S; Mendizabal M; Lin MV; Lichtenstein GR
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
[TBL] [Abstract][Full Text] [Related]
7. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
Shah ED; Coburn ES; Nayyar A; Lee KJ; Koliani-Pace JL; Siegel CA
Aliment Pharmacol Ther; 2020 Mar; 51(5):527-533. PubMed ID: 31990422
[TBL] [Abstract][Full Text] [Related]
8. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy.
van de Meeberg MM; Derikx LA; Sinnige HA; Nooijen P; Schipper DL; Nissen LH
World J Gastroenterol; 2016 Dec; 22(47):10465-10470. PubMed ID: 28058028
[TBL] [Abstract][Full Text] [Related]
9. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
Mackey AC; Green L; Liang LC; Dinndorf P; Avigan M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):265-7. PubMed ID: 17255842
[TBL] [Abstract][Full Text] [Related]
10. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease.
Thayu M; Markowitz JE; Mamula P; Russo PA; Muinos WI; Baldassano RN
J Pediatr Gastroenterol Nutr; 2005 Feb; 40(2):220-2. PubMed ID: 15699701
[No Abstract] [Full Text] [Related]
11. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?
Rosh JR; Gross T; Mamula P; Griffiths A; Hyams J
Inflamm Bowel Dis; 2007 Aug; 13(8):1024-30. PubMed ID: 17480018
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.
Yabe M; Medeiros LJ; Tang G; Wang SA; Ahmed S; Nieto Y; Hu S; Bhagat G; Oki Y; Patel KP; Routbort M; Luthra R; Fanale MA; Bueso-Ramos CE; Jorgensen JL; Vega F; Chen W; Hoehn D; Konoplev S; Milton DR; Wistuba I; Li S; You MJ; Young KH; Miranda RN
Am J Surg Pathol; 2016 May; 40(5):676-88. PubMed ID: 26872013
[TBL] [Abstract][Full Text] [Related]
13. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients.
Yabe M; Medeiros LJ; Tang G; Wang SA; P Patel K; Routbort M; Bhagat G; Bueso-Ramos CE; Jorgensen JL; Luthra R; Chen W; Muzzafar T; Kanagal-Shamanna R; Khoury JD; Daneshbod Y; Davanlou M; Li S; Young KH; Miranda RN
Hum Pathol; 2016 Apr; 50():109-17. PubMed ID: 26997444
[TBL] [Abstract][Full Text] [Related]
14. Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.
Selvaraj SA; Chairez E; Wilson LM; Lazarev M; Bass EB; Hutfless S
Syst Rev; 2013 Jul; 2():53. PubMed ID: 23826928
[TBL] [Abstract][Full Text] [Related]
15. The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006.
Herrinton LJ; Liu L; Abramson O; Jaffe ES
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):49-52. PubMed ID: 21823196
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing Between Hepatosplenic T-cell Lymphoma and γδ T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis.
Yabe M; Medeiros LJ; Wang SA; Tang G; Bueso-Ramos CE; Jorgensen JL; Bhagat G; Chen W; Li S; Young KH; Miranda RN
Am J Surg Pathol; 2017 Jan; 41(1):82-93. PubMed ID: 27755009
[TBL] [Abstract][Full Text] [Related]
17. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?
Subramaniam K; Yeung D; Grimpen F; Joseph J; Fay K; Buckland M; Talaulikar D; Elijah J; Clarke AC; Pavli P; Moore J
Intern Med J; 2014 Mar; 44(3):287-90. PubMed ID: 24621284
[TBL] [Abstract][Full Text] [Related]
18. Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors.
Yabe M; Miranda RN; Medeiros LJ
Hum Pathol; 2018 Apr; 74():5-16. PubMed ID: 29337025
[TBL] [Abstract][Full Text] [Related]
19. Hepatosplenic αβ T-Cell Lymphoma as Second Malignancy in Young Adult Patient With Previously Undiagnosed Ataxia-Telangiectasia.
Jacobs MF; Anderson B; Opipari VP; Mody R
J Pediatr Hematol Oncol; 2020 Aug; 42(6):e463-e465. PubMed ID: 31259827
[TBL] [Abstract][Full Text] [Related]
20. Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction.
Mavilia M; McAuliffe A; Hafeez S; Vaziri H
Clin J Gastroenterol; 2018 Oct; 11(5):364-370. PubMed ID: 29766398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
